GILD

145.65

0.68% -0.99

시간 외 거래: 146.43 0.78 +0.54%

길리어드 사이언스 (GILD)

개요 뉴스 가격 이력 옵션 체인 Financials GILD 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$146.64

열려 있는:

$145.46

하루 거래량:

4.48M

Relative Volume:

0.64

시가총액:

$180.60B

수익:

$29.79B

순이익/손실:

$9.22B

주가수익비율:

19.82

EPS:

7.3494

순현금흐름:

$10.23B

1주 성능:

-2.65%

1개월 성능:

+9.34%

6개월 성능:

-0.67%

1년 성능:

+25.82%

1일 변동 폭

$145.00

$147.68

1주일 범위

$145.00

$151.48

52주 변동 폭

$108.46

$157.29

길리어드 사이언스 Stock (GILD) Company Profile

명칭

Gilead Sciences Inc

부문

Healthcare (1070)

산업

Drug Manufacturers - General (20)

전화

(650) 574-3000

주소

333 LAKESIDE DR, FOSTER CITY, CA

직원

17,000

트위터

@GileadSciences

다음 수익 날짜

2026-10-29

최신 SEC 제출 서류

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
GILD Gilead Sciences Inc	145.65	181.83B	29.79B	9.22B	10.23B	7.3494
LLY Lilly Eli Co	1,124.21	1.00T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	267.08	648.55B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	250.91	439.62B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	147.53	366.28B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	137.48	261.73B	54.66B	13.58B	16.05B	7.0171

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-10	개시	Jefferies	Buy
2026-02-20	개시	Barclays	Equal Weight
2026-02-11	재확인	Needham	Buy
2026-01-07	재개	UBS	Buy
2025-11-24	재개	Truist	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-08-19	업그레이드	Daiwa Securities	Neutral → Outperform
2025-08-08	업그레이드	Truist	Hold → Buy
2025-07-25	업그레이드	Needham	Hold → Buy
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-03-04	재확인	Oppenheimer	Outperform
2025-02-18	업그레이드	Deutsche Bank	Hold → Buy
2025-02-13	업그레이드	DZ Bank	Hold → Buy
2025-01-10	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-11-14	개시	Citigroup	Buy
2024-11-08	다운그레이드	Maxim Group	Buy → Hold
2024-10-21	업그레이드	Leerink Partners	Market Perform → Outperform
2024-10-17	개시	Bernstein	Outperform
2024-10-07	업그레이드	Wells Fargo	Equal Weight → Overweight
2024-07-08	업그레이드	Raymond James	Mkt Perform → Outperform
2024-05-01	재확인	Maxim Group	Buy
2024-04-24	업그레이드	HSBC Securities	Reduce → Hold
2024-02-22	다운그레이드	Truist	Buy → Hold
2023-11-09	개시	Deutsche Bank	Hold
2023-09-08	업그레이드	BofA Securities	Neutral → Buy
2023-09-06	개시	HSBC Securities	Reduce
2023-07-24	재확인	Barclays	Equal Weight
2023-05-16	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-04-28	재개	Piper Sandler	Overweight
2023-01-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	재개	BofA Securities	Neutral
2022-12-09	다운그레이드	DZ Bank	Buy → Hold
2022-10-31	업그레이드	Barclays	Underweight → Equal Weight
2022-10-28	재확인	BMO Capital Markets	Market Perform
2022-10-28	재확인	Cowen	Outperform
2022-10-28	재확인	JP Morgan	Overweight
2022-10-28	재확인	Jefferies	Buy
2022-10-28	업그레이드	Piper Sandler	Neutral → Overweight
2022-10-28	재확인	RBC Capital Mkts	Outperform
2022-10-28	업그레이드	Truist	Hold → Buy
2022-10-28	재확인	Wells Fargo	Equal Weight
2022-10-04	업그레이드	JP Morgan	Neutral → Overweight
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-02-28	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2022-02-02	재확인	BMO Capital Markets	Outperform
2022-02-02	재확인	BofA Securities	Neutral
2022-02-02	재확인	RBC Capital Mkts	Outperform
2022-02-02	재확인	Truist	Hold
2022-02-02	재확인	Wells Fargo	Equal Weight
2022-01-28	업그레이드	Argus	Hold → Buy
2022-01-06	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	재개	Wells Fargo	Equal Weight
2021-12-06	개시	Goldman	Neutral
2021-11-19	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-11-19	재개	Piper Sandler	Neutral
2021-10-20	재개	Cowen	Outperform
2021-07-30	재확인	BMO Capital Markets	Market Perform
2021-07-30	재확인	RBC Capital Mkts	Outperform
2021-04-01	업그레이드	Bernstein	Mkt Perform → Outperform
2021-03-30	업그레이드	Redburn	Neutral → Buy
2021-01-19	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	업그레이드	Guggenheim	Neutral → Buy
2020-11-03	재개	Morgan Stanley	Equal-Weight
2020-10-28	개시	UBS	Neutral
2020-09-30	재개	Jefferies	Buy
2020-09-15	업그레이드	Maxim Group	Hold → Buy
2020-07-31	재확인	Credit Suisse	Neutral
2020-07-31	재확인	Morgan Stanley	Equal-Weight
2020-07-31	재확인	Piper Sandler	Overweight
2020-07-31	재확인	RBC Capital Mkts	Outperform
2020-07-31	재확인	SunTrust	Hold
2020-07-31	재확인	Wells Fargo	Equal Weight
2020-07-20	업그레이드	Credit Suisse	Underperform → Neutral
2020-06-03	업그레이드	SVB Leerink	Mkt Perform → Outperform
2020-05-26	업그레이드	SunTrust	Sell → Hold
2020-05-01	다운그레이드	JP Morgan	Overweight → Neutral
2020-05-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-05-01	다운그레이드	SunTrust	Hold → Sell
2020-04-27	다운그레이드	UBS	Buy → Neutral
2020-04-20	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2020-04-20	다운그레이드	Wells Fargo	Overweight → Equal Weight
2020-04-17	다운그레이드	CFRA	Hold → Sell

모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

09:34 AM

Gilead Sciences stock falls as investors reassess post-earnings rally - ad-hoc-news.de

09:34 AM

06:59 AM

Gilead launches research facility in US for new medicine development - Yahoo Finance

06:59 AM

06:01 AM

NewEdge Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

06:01 AM

Sep 08, 2026

How Bixlenvo Approval At Gilead Sciences (GILD) Has Changed Its Investment Story - simplywall.st

Sep 08, 2026

Gilead opens new building on existing Foster City campus - NBC Bay Area

Sep 08, 2026

Gilead National Ribbon Cutting Ceremony - Post Register

Sep 08, 2026

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Sep 08, 2026

Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa

Sep 08, 2026

Assembly Bio stock gains after exercising Gilead profit option - Investing.com India

Sep 08, 2026

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 08, 2026

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times

Sep 08, 2026

A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan

Sep 08, 2026

Gilead Opens 182,000-Square-Foot Research Center in Foster City - Contract Pharma

Sep 08, 2026

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement - TradingKey

Sep 08, 2026

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines - Gilead Sciences

Sep 08, 2026

Gilead Sciences stock gains on fresh analyst buy rating and Q2 loss swing - AD HOC NEWS

Sep 08, 2026

Gilead Sciences Slides 3.4% as Investors Digest Prior Gains and Ongoing Pricing Risks - Moomoo

Sep 08, 2026

Gilead opens research center as $32 billion US build-out continues - The Pharma Letter

Sep 08, 2026

Gilead Sciences, Inc. $GILD Shares Purchased by Groupe la Francaise - MarketBeat

Sep 08, 2026

California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 08, 2026

Sep 07, 2026

Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market? - Yahoo Finance

Sep 07, 2026

[Press release] FDA approves Gilead’s Bixlenvo™, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens - European AIDS Treatment Group

Sep 07, 2026

Gilead Sciences stock gains after narrowing Q2 loss and firming 2026 guidance - AD HOC NEWS

Sep 07, 2026

Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals - GlobeNewswire Inc.

Sep 07, 2026

Gilead Sciences, Inc. $GILD Holdings Raised by HighTower Advisors LLC - MarketBeat

Sep 07, 2026

VIRGINIA RETIREMENT SYSTEMS ET Al Takes $130.42 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 07, 2026

Gilead Sciences, Inc. (GILD) Stock Analysis: Evaluating the Prospects with a 4.25% Potential Upside - DirectorsTalk Interviews

Sep 07, 2026

Could Gilead Sciences (NASDAQ:GILD) Remain a Nasdaq Focus? - Kalkine Media

Sep 07, 2026

Amundi Has $1.23 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 07, 2026

Sep 06, 2026

Saudi Central Bank Acquires 41,091 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Sep 06, 2026

Sep 05, 2026

Gilead Sciences Strategically Prepares for HIV Market Changes - Intellectia AI

Sep 05, 2026

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? - Yahoo Finance

Sep 05, 2026

Gilead Sciences (NASDAQ:GILD) Lowered to Hold Rating by Wall Street Zen - MarketBeat

Sep 05, 2026

Sep 04, 2026

Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative? - Yahoo Finance

Sep 04, 2026

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? - AOL.com

Sep 04, 2026

Q&A: Gilead's Betty Chiang on what Bixlenvo means for HIV patients on complex regimens - The Pharma Letter

Sep 04, 2026

Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors - ChartMill

Sep 04, 2026

NEOS Investment Management LLC Has $120.08 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 04, 2026

TD Waterhouse Canada Inc. Sells 70,572 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Sep 04, 2026

AXQ Capital LP Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 04, 2026

Sep 03, 2026

Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Sep 03, 2026

Gilead Sciences (GILD) Chairman & CEO Daniel O'Day Sells 15,000 Shares - GuruFocus

Sep 03, 2026

Nykredit A S Makes New $177.13 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 03, 2026

iSAM Funds UK Ltd Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 03, 2026

B. Metzler seel. Sohn & Co. AG Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 03, 2026

Sep 02, 2026

Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock - MarketBeat

Sep 02, 2026

Gilead (NASDAQ: GILD) CEO sells 15,000 shares near $150 - Stock Titan

Sep 02, 2026

Gilead Sciences stock gains as analysts turn more positive - AD HOC NEWS

Sep 02, 2026